

AMNEAL IS EXPANDING ACCESS TO CREXONT

We are committed to increasing access to **CREXONT®** (carbidopa and levodopa) extended-release capsules

We continue to work closely with insurers across the country to secure formulary coverage and are pleased to announce major access wins that expand availability to millions of patients nationwide.

CREXONT can be accessed* commercially through the following:

- UnitedHealthcare
- CVS Caremark
- Kaiser Permanente
- Federal Employees Program
- Cigna

*Step therapy may be required: Patient has tried and failed prior generic carbidopa and levodopa product

These additions mean that millions of patients now have access to CREXONT through their health plans. With continued formulary expansion efforts, we are ensuring that more patients can benefit from an extended-release oral carbidopa and levodopa treatment option.

Why expanding access matters:

- **More coverage, more patients helped** – With increasing payer adoption, more people can access CREXONT as a treatment option.
- **Commitment to affordability** – As access grows, patients may have more affordable co-pay options, ensuring they can stay on therapy.
- **Supporting healthcare professionals & patients** – With broader formulary inclusion, healthcare providers can confidently prescribe CREXONT knowing that it is covered for many of their patients.



Stay up-to-date on CREXONT coverage

For the latest information on CREXONT's expanding access please visit our website.



CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC.
© 2025 Amneal Pharmaceuticals LLC.
Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.
All rights reserved. PP-ADP-CREX-US-0012 03/2025

